#ASH17: Spark triggers a backlash as early hemophilia A gene therapy data looks shaky – Endpoints News
Endpoints News |
#ASH17: Spark triggers a backlash as early hemophilia A gene therapy data looks shaky
Endpoints News Following up on its impressive work on a new gene therapy for hemophilia B, Spark Therapeutics $ONCE has offered a peek at its cards on the early data from a separate program it has on hemophilia A. And it's clear that there's a lot of work to be done … ASH17: Spark gene therapy falls behind BioMarin in hemophilia Gene Therapy Nearly Eliminates Hemophilia B Bleeding Episodes, Trial Shows This Bull Is Sticking By Spark Therapeutics Inc (ONCE) and Its Novel … |
